Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Davies

Showing results (1-10 of 314) with videos related to

Pageof 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Regulation, role, and targeting of Akt in cancerMichael A Davies
Cancer Journal (Sudbury, Mass.)|March 29, 2012
The role of the PI3K-AKT pathway in melanomaMichael A Davies
Cancer Discovery|May 6, 2014
Finding the right balance of BRAF inhibition in melanomaMichael A Davies
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2020
Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?Michael A Davies
Cancer Journal (Sudbury, Mass.)|March 29, 2012
Special issue on melanomaMichael A Davies
Advances in Pharmacology (San Diego, Calif.)|September 11, 2012
Targeted therapy for brain metastasesMichael A Davies
Cancer Cytopathology|April 17, 2015
Role and complexity of next-generation sequencing in melanomaMichael A Davies
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Molecular approaches to tumor inhibition in melanomaMichael A Davies
Hematology/Oncology Clinics of North America|June 2, 2014
Targeted therapy resistance mechanisms and therapeutic implications in melanomaGuo Chen, Michael A Davies
Melanoma Management|November 24, 2015
Converting biology into clinical benefit: lessons learned from BRAF inhibitorsJennifer McQuade, Michael A Davies
Pageof 32

Showing results (1-10 of 314) with videos related to

Sort By:
Pageof 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Regulation, role, and targeting of Akt in cancerMichael A Davies
Cancer Journal (Sudbury, Mass.)|March 29, 2012
The role of the PI3K-AKT pathway in melanomaMichael A Davies
Cancer Discovery|May 6, 2014
Finding the right balance of BRAF inhibition in melanomaMichael A Davies
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2020
Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?Michael A Davies
Cancer Journal (Sudbury, Mass.)|March 29, 2012
Special issue on melanomaMichael A Davies
Advances in Pharmacology (San Diego, Calif.)|September 11, 2012
Targeted therapy for brain metastasesMichael A Davies
Cancer Cytopathology|April 17, 2015
Role and complexity of next-generation sequencing in melanomaMichael A Davies
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Molecular approaches to tumor inhibition in melanomaMichael A Davies
Hematology/Oncology Clinics of North America|June 2, 2014
Targeted therapy resistance mechanisms and therapeutic implications in melanomaGuo Chen, Michael A Davies
Melanoma Management|November 24, 2015
Converting biology into clinical benefit: lessons learned from BRAF inhibitorsJennifer McQuade, Michael A Davies
Pageof 32